Ionis to hold first quarter 2022 financial results webcast
Get Alerts IONS Hot Sheet
Join SI Premium – FREE
Webcast scheduled for Wednesday, May 4 at 11:30 a.m. Eastern Time
CARLSBAD, Calif., April 20, 2022 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, May 4th at 11:30 a.m. Eastern Time to discuss its first quarter financial results and report on pipeline and business progress.
The webcast may be accessed at https://ir.ionispharma.com/events-and-presentations/upcoming-events. A replay will be available for a limited time at the same address.
About Ionis Pharmaceuticals, Inc.For more than 30 years, Ionis has been the leader in RNA-targeted therapy, pioneering new markets and changing standards of care with its novel antisense technology. Ionis currently has three marketed medicines and a premier late-stage pipeline highlighted by industry-leading cardiovascular and neurological franchises. Our scientific innovation began and continues with the knowledge that sick people depend on us, which fuels our vision of becoming a leading, fully integrated biotechnology company.
To learn more about Ionis visit www.ionispharma.com and follow us on Twitter @ionispharma.
View original content to download multimedia:https://www.prnewswire.com/news-releases/ionis-to-hold-first-quarter-2022-financial-results-webcast-301528583.html
SOURCE Ionis Pharmaceuticals, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BMO Capital Starts Ionis Pharmaceuticals (IONS) at Market Perform
- Warren Wilson College Receives $350,000 Grant to Advance Civic Environmentalism and Climate Stewardship
- Meditrina Appoints Janis Smith-Gomez to Board of Directors
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
Twitter, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share